Experts Video Reports: Genitourinary Cancers track

Learn about key results illustrated by slides from the sessions!

The Genitourinary Cancers track 2019 is supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson . The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

ESMO Congress 2019: Expert Video Report on Prostate cancer

Reporting from ESMO 2019 Congress, Johann de Bono comments on practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC). He features the results from the CARD study on best sequence treatment and from the PROfound trial with olaparib in patients whose tumours have homologous recombination repair gene alterations. He explains the need for molecular profiling of advanced prostate cancer which may have a major impact on prostate cancer management in the future.

ASCO 2019: Expert Video Report on Prostate cancer

E. Efstathiou reports on study results presented on prostate cancer at ASCO 2019. She explains the benefits of adding hormonal agents early in the disease spectrum, and discusses the prospect of combinatorial strategies based on biomarkers selection.

- LBA2 / Overall survival (OS) results of ENZAMET (ANZUP 1304) trial
- Abstract 5006 / First results from TITAN trial
- Abstract 5008 / Alliance A031201: A phase III trial in mCRPC

AACR 2019: Expert Video Report on Liquid Biopsy

Reporting from AACR 2019 in Atlanta, F-C. Bidard comments on clinical utility of CTCs and ctDNA as biomarkers based on the results from two studies in breast and prostate cancer.

ASCO GU 2019: Expert Video Report on Prostate Cancer

Reporting from ASCO GU, Silke Gillessen (Manchester) comments on the results from major studies on Prostate Cancer that were presented during this meeting:

  • Abstract 140 ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer; K. Fizazi
  • Abstract 687: Phase 3 study of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: The ARCHES trial; A.J. Armstrong

ASCO GU 2019: Expert Video Report on Renal Cell Carcinoma

Reporting from ASCO GU, Bradley McGregor comments on Renal cell carcinoma studies results: JAVELIN, KEYNOTE-426, CheckMate 214, KEYNOTE-427 and a phase II study of atezolizumab and bevacizumab


Track 2018: Videos reports from ESMO Congress and ASCO conference

ESMO 2018 Congress: Highlights in advanced renal cell carcinoma

Dr Robert Motzer reports on key results from ESMO 2018 Congress: LBA6_PR: JAVELIN Renal 101: a randomised, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma.

Perspectives from ASCO 2018: Advances in metastatic RCC - the CARMENA study

Arnaud Mejean reporting from ASCO 2018 explains that the CARMENA trial was designed to learn if nephrectomy is still necessary in metastatic renal cell carcinoma (mRCC)

ASCO GU: Highlights on Renal Cell Cancer: IMmotion151 and other combination studies

Reporting from ASCO GU 2018, Bernard Escudier states that the results from studies presented are likely to be practice changing for the treatment of patients with renal cell cancer (RCC), regarding first-line options and patients' selection.

ASCO GU: Highlights on non metastatic Castration-Resistant Prostate Cancer, the SPARTAN and PROSPER trials

Reporting from ASCO GU 2018, Stephane Oudard highlights two large randomised phase III studies relevant for clinical practice (SPARTAN with apalutamide and PROSPER with enzalutamide) in term of providing new treatment options for the group of patients with non-metastatic castration-resistant prostate cancer (CRPC) who are at high risk of developing metastasis.


More ESMO videos on Genitourinary Cancers from the ESMO Channel

View the full playlist on the ESMO Channel

ESMO thanks the sponsor for supporting this track in 2019: